Shandong Weigao Group Medical Polymer Company Limited provided earnings guidance for the year ended 31 December 2023. For the year, the company expects to record a decrease in revenue in the range of 2% to 5% during the Reporting Period as compared with the revenue recognised due to the accounting restatement as a result of business combination under common control for the same period last year; and a decrease of net profit attributable to the owners of the Company for the Reporting Period in the range of 25% to 30% as compared with the Net Profit reported with consideration of the accounting restatement as a result of business combination under common control for the same period last year.
Shandong Weigao Group Medical Polymer Company Limited
Equities
1066
CNE100000171
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.34 HKD | +2.69% | +6.80% | -29.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.83% | 3.04B | |
+10.80% | 27.84B | |
-14.68% | 2.56B | |
+11.64% | 2.33B | |
+2.96% | 1.99B | |
-11.65% | 1.87B | |
-1.67% | 1.49B | |
+2.19% | 1.27B | |
+3.72% | 1.12B | |
+16.22% | 1.15B |
- Stock Market
- Equities
- 1066 Stock
- News Shandong Weigao Group Medical Polymer Company Limited
- Shandong Weigao Group Medical Polymer Company Limited Provides Earnings Guidance for the Year Ended 31 December 2023